Compare Inovio Pharmaceuticals Inc (INO) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.68. The key difference: YieldMax Magnificent 7 Fund of Option Income ETFs is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | YMAG | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $2.87 | $15.98 |
52-Week Low | $1.05 | $11.00 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.63, up 0.17% with a neutral technical signal. The ETF provides weekly dividend distributions, recently ranging from $0.07 to $0.40 per share. Key financial ratios are unavailable, but the fund's strategy focuses on option income from Magnificent Seven stocks. Recent news highlights consistent distribution announcements and tactical performance discussions.
Outlook hinges on option income strategy effectiveness in volatile markets. Opportunities include high yield potential, but risks involve NAV decay and expense ratio drag. Investor sentiment is mixed, with some analysts citing underperformance versus benchmarks amid low implied volatility reducing yield potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
